<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01753674</url>
  </required_header>
  <id_info>
    <org_study_id>H12-256</org_study_id>
    <secondary_id>TAS-12-035</secondary_id>
    <nct_id>NCT01753674</nct_id>
  </id_info>
  <brief_title>The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome</brief_title>
  <official_title>The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Connecticut</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Connecticut</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our hypothesis is that TA-65, a dietary supplement will help to reduce insulin resistance and&#xD;
      plasma glucose in individuals classified with metabolic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is double blind cross over randomized clinical trial. The supplement and placebo will be&#xD;
      provided by TA Science, Inc. and prepared as described below. Subjects will be randomly&#xD;
      allocated to consume either a daily serving of TA-65 (two capsules per day of 8 mg each)&#xD;
      (please see attached label) or a placebo for 12 weeks. Randomization will be done in a&#xD;
      sequential manner; the first subject will be allocated to supplement A and the next one to&#xD;
      supplement B and so on. After a 3-week washout, they will be allocated to the alternate&#xD;
      treatment for additional 12 weeks. Supplements (TA-65 or placebo) will be taken twice daily&#xD;
      with a meal.&#xD;
&#xD;
      Participants will be advised not to change their diet or exercise protocols during the 27&#xD;
      week intervention. Volunteers will be required to provide a 5-day dietary record before&#xD;
      starting the study, at the end of each supplement period (TA-65 or placebo) and at the end of&#xD;
      the washout period. Subjects will have to fill an exercise questionnaire during the same&#xD;
      times to ensure that there are no changes in physical activity. Participants will be asked to&#xD;
      report to the department every 4 weeks for checking compliance on supplement intake and to&#xD;
      assess weight and blood pressure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    non-compliance issues&#xD;
  </why_stopped>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma insulin levels</measure>
    <time_frame>27 weeks</time_frame>
    <description>The supplement is anticipated to decrease insulin resistance in individuals with metabolic syndrome. The investigators will measure plasma insulin and plasma glucose as outcomes measures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma HDL cholesterol</measure>
    <time_frame>27 weeks</time_frame>
    <description>It is expected that the TA-65 supplement will increase plasma HDL, another characteristic of metabolic syndrome</description>
  </secondary_outcome>
  <other_outcome>
    <measure>blood pressure</measure>
    <time_frame>27 weeks</time_frame>
    <description>It is expected that the supplement will decrease blood pressure, another outcome of metabolic syndrome</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>TA-65</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TA-65 will be provided to volunteers for 12 weeks, two pills per day of 8 mg each</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be provided to volunteers for 12 weeks, 2 pills per day of 8 mg each.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>TA-65</intervention_name>
    <description>TA-65 will be provided to volunteers, 2 pills per day of 8 mg each</description>
    <arm_group_label>TA-65</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo supplement will be provided to volunteers, 2 pills per day of 8 mg each</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The inclusion criteria are:&#xD;
&#xD;
        men and women (40-70 y) with metabolic syndrome which means having at least 3 of the&#xD;
        following characteristics:&#xD;
&#xD;
          -  Blood pressure &gt; 130/85 mm Hg&#xD;
&#xD;
          -  plasma glucose &gt; 100 mg/dL&#xD;
&#xD;
          -  plasma triglycerides &gt; 150 mg/dL&#xD;
&#xD;
          -  HDL cholesterol &lt; 40 mg/dL (men) and &lt; 50 mg/dL (women)&#xD;
&#xD;
          -  waist circumference &gt;102 cm (men) and â‰¥ 88 cm (women)&#xD;
&#xD;
          -  Women of childbearing age should be using contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Exclusion criteria will be&#xD;
&#xD;
          -  self-reported diabetes mellitus&#xD;
&#xD;
          -  coronary heart disease&#xD;
&#xD;
          -  triglycerides greater than 400 mg/dL&#xD;
&#xD;
          -  Fasting glucose greater than 126 mg/dL&#xD;
&#xD;
          -  Blood pressure greater than 140/100 mmg Hg&#xD;
&#xD;
          -  history of stroke&#xD;
&#xD;
          -  Use of alcohol at an elevated rate (more than two drinks per day)&#xD;
&#xD;
          -  Renal problems&#xD;
&#xD;
          -  liver disease&#xD;
&#xD;
          -  cancer&#xD;
&#xD;
          -  pregnancy and lactation&#xD;
&#xD;
          -  severe infectious diseases&#xD;
&#xD;
          -  autoimmune disease currently under treatment&#xD;
&#xD;
          -  current hormone therapy&#xD;
&#xD;
          -  previous treatment with TA-65.&#xD;
&#xD;
          -  Intake of glucose-lowering prescriptions&#xD;
&#xD;
          -  Use of immunosuppressants, lithium or supplements such as Sulphonylureas (Glucotrol,&#xD;
             Amaryl), Thiazolidinedione (Avandia, ACTOS,), Meglitinides (Prandin, Starlix),&#xD;
             Biguanides (Metformin), Alpha-glucosidase inhibitors (Precose, Glyset), dipeptidyl&#xD;
             peptidase (DPP)-4 inhibitors (Januvia, Onglyza)&#xD;
&#xD;
          -  high dose chromium or cinnamon supplements&#xD;
&#xD;
          -  Consistent intake of vitamin, mineral, or multivitamin supplements prior to&#xD;
             recruitment may be admitted into the study if they plan on maintaining their current&#xD;
             supplement program.&#xD;
&#xD;
        However, subjects may not participate if they begin taking a new supplement during the&#xD;
        27-wk study period.&#xD;
&#xD;
        -Subjects will also be asked to refrain from taking any additional supplements, including&#xD;
        fish oil, herb and concentrated antioxidant sources.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria-Luz Fernandez, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Connecticut</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Connecticut</name>
      <address>
        <city>Storrs</city>
        <state>Connecticut</state>
        <zip>06269</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.tasciences.com/</url>
    <description>Sponsor Company</description>
  </link>
  <reference>
    <citation>Maubaret CG, Salpea KD, Jain A, Cooper JA, Hamsten A, Sanders J, Montgomery H, Neil A, Nair D, Humphries SE; HIFMECH consortium, Simon Broome Research Group. Telomeres are shorter in myocardial infarction patients compared to healthy subjects: correlation with environmental risk factors. J Mol Med (Berl). 2010 Aug;88(8):785-94. doi: 10.1007/s00109-010-0624-3. Epub 2010 Apr 11.</citation>
    <PMID>20383691</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>December 17, 2012</study_first_submitted>
  <study_first_submitted_qc>December 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2012</study_first_posted>
  <last_update_submitted>May 27, 2015</last_update_submitted>
  <last_update_submitted_qc>May 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metabolic syndrome, insulin resistance, HDL cholesterol,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

